Colgate-Palmolive (CL) Director Acquires 228 Shares at $82.13
Brian Newman, a director of Colgate-Palmolive Co. (CL), reported a non-derivative acquisition of 228 shares of common stock on 10/01/2025 at a price of $82.13 per share.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Brian Newman, a director of Colgate-Palmolive Co. (CL), reported a non-derivative acquisition of 228 shares of common stock on 10/01/2025 at a price of $82.13 per share. Following the transaction he directly beneficially owns 5,065 shares and indirectly holds 36 shares through a family trust. The filing identifies the purchase code A(1), and the explanation states this represents a portion of the annual cash retainer deferred into a stock unit account under the company’s Deferred Compensation Plan for Non-Employee Directors. The Form 4 was signed by an attorney-in-fact on 10/03/2025.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 228 | $82.13 | $19K |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- F1. Portion of annual cash retainer deferred to a stock unit account pursuant to the Deferred Compensation Plan for Non-Employee Directors.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Colgate-Palmolive director Brian Newman report on Form 4?
Why was the purchase coded A(1) in the CL Form 4?
When was the Form 4 for this transaction signed and filed?
Did the Form 4 disclose any derivative transactions for Brian Newman?
AI-generated analysis. How Rhea-AI works. Not financial advice.